Long-term Bitcoin holders’ selling pressure is nearing saturation, according to K33 Research. The two-year dormant supply could level off and start climbing againLong-term Bitcoin holders’ selling pressure is nearing saturation, according to K33 Research. The two-year dormant supply could level off and start climbing again

Long-Term Bitcoin Holders Near Sell-Side Saturation, Says K33

For feedback or concerns regarding this content, please contact us at [email protected]
  • Long-term Bitcoin holders’ selling pressure is nearing saturation, according to K33 Research.
  • The two-year dormant supply could level off and start climbing again as distribution tapers.

Selling pressure from long-term Bitcoin holders is approaching saturation, according to K33 Research. After two years of the old supply returning to the market, the rate of redistribution from old holders has begun to slow. Many previously dormant coins have been released, limiting the scope for further selling for this group.

K33 notes that since 2024, approximately 1.6 million coins more than two years old have returned to the market. This is a significant amount, and this movement is not simply a technical change of address. Data indicates that this flow is directly related to the realization of profits by early holders who chose to sell when market liquidity improved. However, after this long period, the rate of supply leaving the hands of old holders has begun to slow.

Bitcoin Selling Pressure Nears Its Final Stretch

Historically, the period from 2024 to 2025 was one of the largest periods of the return of old Bitcoin supply to the market, second only to the 2017 cycle. Approximately one-fifth of the total supply has already undergone redistribution.

However, this figure is precisely what leads K33 to assess that selling pressure from this group is approaching its limit. In other words, most of the coins that could have been sold have already changed hands.

According to K33, the share of coins idle for more than two years is leveling off after several cycles of decline. The firm expects this downtrend to halt and potentially turn upward in 2026, signaling a shift from a distribution-heavy environment to one where supply becomes more balanced.

Still, a drop in selling pressure doesn’t automatically translate into a fast market reaction. Demand remains a crucial role. Without consistent capital flows, the effects of a weakening distribution can be felt to a limited extent. Nevertheless, reduced supply from long-term holders usually gives the market room to breathe, especially when demand persists.

Furthermore, ownership shift patterns are also changing. K33 believes that coins leaving the hands of long-term holders tend to go to those with longer-term horizons. This process is slow and subtle, but its impact is felt on the market structure. Bitcoin selling pressure, which used to occur regularly, is now becoming less frequent.

On December 15, we reported that demand for crypto ETFs for Bitcoin and Ethereum is now matching, or even exceeding, the newly issued supply. The ETF’s accumulation indicates a shift in coins from weaker to stronger holders.

A few days earlier, on December 12, we highlighted Bank of America’s plans to create a Bitcoin-collateralized credit product, allowing holders to access liquidity without having to sell.

A week ago, we also reported on PNC Bank becoming the first major US bank to offer integrated Bitcoin spot trading services for private banking clients through a partnership with Coinbase.

As of press time, BTC is changing hands at about $86,422, down 0.30% over the last 24 hours and 6.01% over the last 7 days.

]]>
Market Opportunity
Belong Logo
Belong Price(LONG)
$0.001937
$0.001937$0.001937
-1.02%
USD
Belong (LONG) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09